Terms: = Leukemia AND VHL, HRCA1, P40337, 7428, ENSG00000134086, RCA1, VHL1
58 results:
1. Discovery of a Meisoindigo-Derived PROTAC as the ATM Degrader: Revolutionizing Colorectal Cancer Therapy via Synthetic Lethality with ATR Inhibitors.
Liu TT; Wang Q; Zhou Y; Ye B; Liu T; Yan L; Fan J; Xu J; Zhou Y; Xia Z; Deng X
J Med Chem; 2024 May; 67(9):7620-7634. PubMed ID: 38634707
[TBL] [Abstract] [Full Text] [Related]
2. Discovery of a novel, highly potent EZH2 PROTAC degrader for targeting non-canonical oncogenic functions of EZH2.
Velez J; Dale B; Park KS; Kaniskan HÜ; Yu X; Jin J
Eur J Med Chem; 2024 Mar; 267():116154. PubMed ID: 38295690
[TBL] [Abstract] [Full Text] [Related]
3. Opportunistic genetic screening increases the diagnostic yield and is medically valuable for care of patients and their relatives with hereditary cancer.
Fernández-Castillejo S; Roig B; Melé M; Serrano S; Salvat M; Querol M; Brunet J; Pineda M; Cisneros A; Parada D; Badia J; Borràs J; Rodríguez-Balada M; Gumà J
J Med Genet; 2023 Dec; 61(1):69-77. PubMed ID: 37591735
[TBL] [Abstract] [Full Text] [Related]
4. Co-targeting BCL-XL and BCL-2 by PROTAC 753B eliminates leukemia cells and enhances efficacy of chemotherapy by targeting senescent cells.
Jia Y; Han L; Ramage CL; Wang Z; Weng CC; Yang L; Colla S; Ma H; Zhang W; Andreeff M; Daver N; Jain N; Pemmaraju N; Bhalla K; Mustjoki S; Zhang P; Zheng G; Zhou D; Zhang Q; Konopleva M
Haematologica; 2023 Oct; 108(10):2626-2638. PubMed ID: 37078252
[TBL] [Abstract] [Full Text] [Related]
5. PIN1 and CDK1 cooperatively govern pvhl stability and suppressive functions.
Chen J; Li M; Liu Y; Guan T; Yang X; Wen Y; Zhu Y; Xiao Z; Shen X; Zhang H; Tang H; Liu T
Cell Death Differ; 2023 Apr; 30(4):1082-1095. PubMed ID: 36813923
[TBL] [Abstract] [Full Text] [Related]
6. Targeted Degradation of PRC1 Components, BMI1 and RING1B, via a Novel Protein Complex Degrader Strategy.
Park KS; Qin L; Kabir M; Luo K; Dale B; Zhong Y; Kim A; Wang GG; Kaniskan HÜ; Jin J
Adv Sci (Weinh); 2023 Apr; 10(10):e2205573. PubMed ID: 36737841
[TBL] [Abstract] [Full Text] [Related]
7. Sunitinib-based Proteolysis Targeting Chimeras (PROTACs) reduced the protein levels of FLT-3 and c-KIT in leukemia cell lines.
Zhai J; Li C; Sun B; Wang S; Cui Y; Gao Q; Sang F
Bioorg Med Chem Lett; 2022 Dec; 78():129041. PubMed ID: 36332882
[TBL] [Abstract] [Full Text] [Related]
8. vhl tumor suppressor as a novel potential candidate biomarker in papillary thyroid carcinoma.
Todorović L; Stanojević B
Biomol Biomed; 2023 Feb; 23(1):26-36. PubMed ID: 36036061
[TBL] [Abstract] [Full Text] [Related]
9. Novel Germline
Provenzano A; Chetta M; De Filpo G; Cantini G; La Barbera A; Nesi G; Santi R; Martinelli S; Rapizzi E; Luconi M; Maggi M; Mannelli M; Ercolino T; Canu L
Medicina (Kaunas); 2022 Aug; 58(8):. PubMed ID: 36013579
[TBL] [Abstract] [Full Text] [Related]
10. BRD4 Inhibitor GNE-987 Exerts Anticancer Effects by Targeting Super-Enhancer-Related Gene LYL1 in Acute Myeloid leukemia.
Sang X; Zhang Y; Fang F; Gao L; Tao Y; Li X; Zhang Z; Wang J; Tian Y; Li Z; Yao D; Wu Y; Chu X; Zhang K; Ma L; Lu L; Chen Y; Yu J; Zhuo R; Wu S; Zhang Z; Pan J; Hu S
J Immunol Res; 2022; 2022():7912484. PubMed ID: 35958877
[TBL] [Abstract] [Full Text] [Related]
11. Differences in actionable genomic alterations between brain metastases and non‑brain metastases in patients with non‑small cell lung cancer.
Nian R; Jiang H; Zhao J; Hou W; Zhang H; Ma J; Lv P; Jiang L; Wang Y; Xu Y; Wu S; Lou J; Li W
Int J Oncol; 2022 Sep; 61(3):. PubMed ID: 35796015
[TBL] [Abstract] [Full Text] [Related]
12. Targeted Degradation of mRNA Decapping Enzyme DcpS by a vhl-Recruiting PROTAC.
Swartzel JC; Bond MJ; Pintado-Urbanc AP; Daftary M; Krone MW; Douglas T; Carder EJ; Zimmer JT; Maeda T; Simon MD; Crews CM
ACS Chem Biol; 2022 Jul; 17(7):1789-1798. PubMed ID: 35749470
[TBL] [Abstract] [Full Text] [Related]
13. PBX1, EMCN and ERG are associated with the sub-clusters and the prognosis of vhl mutant clear cell renal cell carcinoma.
Wang H; Wang X; Xu L; Zhang J
Sci Rep; 2022 May; 12(1):8955. PubMed ID: 35624190
[TBL] [Abstract] [Full Text] [Related]
14. Discovery of a dual WDR5 and Ikaros PROTAC degrader as an anti-cancer therapeutic.
Li D; Yu X; Kottur J; Gong W; Zhang Z; Storey AJ; Tsai YH; Uryu H; Shen Y; Byrum SD; Edmondson RD; Mackintosh SG; Cai L; Liu Z; Aggarwal AK; Tackett AJ; Liu J; Jin J; Wang GG
Oncogene; 2022 Jun; 41(24):3328-3340. PubMed ID: 35525905
[TBL] [Abstract] [Full Text] [Related]
15. Strategies to Reduce the On-Target Platelet Toxicity of Bcl-x
Negi A; Voisin-Chiret AS
Chembiochem; 2022 Jun; 23(12):e202100689. PubMed ID: 35263486
[TBL] [Abstract] [Full Text] [Related]
16. Clinical considerations for the design of PROTACs in cancer.
Nieto-Jiménez C; Morafraile EC; Alonso-Moreno C; Ocaña A
Mol Cancer; 2022 Mar; 21(1):67. PubMed ID: 35249548
[TBL] [Abstract] [Full Text] [Related]
17. Development of a BCL-xL and BCL-2 dual degrader with improved anti-leukemic activity.
Lv D; Pal P; Liu X; Jia Y; Thummuri D; Zhang P; Hu W; Pei J; Zhang Q; Zhou S; Khan S; Zhang X; Hua N; Yang Q; Arango S; Zhang W; Nayak D; Olsen SK; Weintraub ST; Hromas R; Konopleva M; Yuan Y; Zheng G; Zhou D
Nat Commun; 2021 Nov; 12(1):6896. PubMed ID: 34824248
[TBL] [Abstract] [Full Text] [Related]
18. A selective WDR5 degrader inhibits acute myeloid leukemia in patient-derived mouse models.
Yu X; Li D; Kottur J; Shen Y; Kim HS; Park KS; Tsai YH; Gong W; Wang J; Suzuki K; Parker J; Herring L; Kaniskan HÜ; Cai L; Jain R; Liu J; Aggarwal AK; Wang GG; Jin J
Sci Transl Med; 2021 Sep; 13(613):eabj1578. PubMed ID: 34586829
[TBL] [Abstract] [Full Text] [Related]
19. JAK2 unmutated erythrocytosis: current diagnostic approach and therapeutic views.
Gangat N; Szuber N; Pardanani A; Tefferi A
Leukemia; 2021 Aug; 35(8):2166-2181. PubMed ID: 34021251
[TBL] [Abstract] [Full Text] [Related]
20. Monitoring of clonal evolution of acute myeloid leukemia identifies the leukemia subtype, clinical outcome and potential new drug targets for post-remission strategies or relapse.
Onecha E; Rapado I; Luz Morales M; Carreño-Tarragona G; Martinez-Sanchez P; Gutierrez X; Sáchez Pina JM; Linares M; Gallardo M; Martinez-López J; Ayala R
Haematologica; 2021 Sep; 106(9):2325-2333. PubMed ID: 32732356
[TBL] [Abstract] [Full Text] [Related]
[Next]
